|
1
|
Langley RG, Krueger GG and Griffiths CE:
Psoriasis: Epidemiology, clinical features, and quality of life.
Ann Rheum Dis. 64:(Suppl 2). 18–25. 2005. View Article : Google Scholar
|
|
2
|
Weger W: Current status and new
developments in the treatment of psoriasis and psoriatic arthritis
with biological agents. Br J Pharmacol. 160:810–820. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Prieto-Pérez R, Cabaleiro T, Daudén E,
Ochoa D, Roman M and Abad-Santos F: Genetics of psoriasis and
pharmacogenetics of biological drugs. Autoimmune Dis.
2013:6130862013.PubMed/NCBI
|
|
4
|
Rodgers M, Epstein D, Bojke L, Yang H,
Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, et
al: Etanercept, infliximab and adalimumab for the treatment of
psoriatic arthritis: A systematic review and economic evaluation.
Health Technol Assess. 15:1–329. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ayroldi E, Bastianelli A, Cannarile L,
Petrillo MG, Delfino DV and Fierabracci A: A pathogenetic approach
to autoimmune skin disease therapy: Psoriasis and biological drugs,
unresolved issues and future directions. Curr Pharm Des.
17:3176–3190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Winterfield LS, Menter A, Gordon K and
Gottlieb A: Psoriasis treatment: Current and emerging directed
therapies (Review). Ann Rheum Dis. 64:(Suppl 2). 87–90. 2005.
View Article : Google Scholar
|
|
7
|
Papp KA: Etanercept in psoriasis. Expert
Opin Pharmacother. 5:2139–2146. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nestorov I, Zitnik R, DeVries T, Nakanishi
AM, Wang A and Banfield C: Pharmacokinetics of subcutaneously
administered etanercept in subjects with psoriasis. Br J Clin
Pharmacol. 62:435–445. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Knight DM, Trinh H, Le J, Siegel S, Shealy
D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, et al:
Construction and initial characterization of a mouse-human chimeric
anti-TNF antibody. Mol Immunol. 30:1443–1453. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gottlieb AB: Tumor necrosis factor
blockade: Mechanism of action. J Investig Dermatol Symp Proc.
12:1–4. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gottlieb AB, Chamian F, Masud S, Cardinale
I, Abello MV, Lowes MA, Chen F, Magliocco M and Krueger JG: TNF
inhibition rapidly down-regulates multiple proinflammatory pathways
in psoriasis plaques. J Immunol. 175:2721–2729. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Akira S and Takeda K: Toll-like receptor
signalling. Nat Rev Immunol. 4:499–511. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Terhorst D, Kalali BN, Ollert M, Ring J
and Mempel M: The role of toll-like receptors in host defenses and
their relevance to dermatologic diseases. Am J Clin Dermatol.
11:1–10. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Begon E, Michel L, Flageul B, Beaudoin I,
Jean-Louis F, Bachelez H, Dubertret L and Musette P: Expression,
subcellular localization and cytokinic modulation of Toll-like
receptors (TLRs) in normal human keratinocytes: TLR-2 up-regulation
in psoriatic skin. Eur J Dermatol. 17:497–506. 2007.PubMed/NCBI
|
|
15
|
Miller LS and Modlin RL: Toll-like
receptors in the skin. Semin Immunopathol. 29:15–26. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sandig H and Bulfone-Paus S: TLR signaling
in mast cells: Common and unique features. Front Immunol.
3:1852012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Miller LS: Toll-like receptors in skin.
Adv Dermatol. 24:71–87. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Krishna S, Ray A, Dubey SK, Larrouy-Maumus
G, Chalut C, Castanier R, Noguera A, Gilleron M, Puzo G, Vercellone
A, et al: Lipoglycans contribute to innate immune detection of
mycobacteria. PLoS One. 6:e284762011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zughaier SM: Neisseria meningitidis
capsular polysaccharides induce inflammatory responses via TLR-2
and TLR4-MD-2. J Leukoc Biol. 89:469–480. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bieback K, Lien E, Klagge IM, Avota E,
Schneider-Schaulies J, Duprex WP, Wagner H, Kirschning CJ, Ter
Meulen V and Schneider-Schaulies S: Hemagglutinin protein of
wild-type measles virus activates toll-like receptor 2 signaling. J
Virol. 76:8729–8736. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sloane JA, Blitz D, Margolin Z and
Vartanian T: A clear and present danger: Endogenous ligands of
toll-like receptors. Neuromolecular Med. 12:149–163. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Morizane S, Yamasaki K, Mühleisen B, Kotol
PF, Murakami M, Aoyama Y, Iwatsuki K, Hata T and Gallo RL:
Cathelicidin antimicrobial peptide LL-37 in psoriasis enables
keratinocyte reactivity against TLR-9 ligands. J Invest Dermatol.
132:135–143. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Miller AM: Role of IL-33 in inflammation
and disease. J Inflamm (Lond). 8:222011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Balato A, Lembo S, Mattii M, Schiattarella
M, Marino R, De Paulis A, Balato N and Ayala F: IL-33 is secreted
by psoriatic keratinocytes and induces pro-inflammatory cytokines
via keratinocyte and mast cell activation. Exp Dermatol.
21:892–894. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Balato A, Schiattarella M, Lembo S, Mattii
M, Prevete N, Balato N and Ayala F: Interleukin-1 family members
are enhanced in psoriasis and suppressed by vitamin D and retinoic
acid. Arch Dermatol Res. 305(3): 255–262. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Psoriasis and skin pain: instrumental and
biological evaluations. Patruno C, Napolitano M, Balato N, Ayala F,
Megna M, Patrì A, Cirillo T and Balato A: Acta Derm Venereol.
95(4): 432–438. 2015.PubMed/NCBI
|
|
27
|
Theoharides TC, Zhang B, Kempuraj D, Tagen
M, Vasiadi M, Angelidou A, Alysandratos KD, Kalogeromitros D, Asadi
S, Stavrianeas N, et al: IL-33 augments substance P-induced VEGF
secretion from human mast cells and is increased in psoriatic skin.
Proc Natl Acad Sci USA. 107:4448–4453. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hueber AJ, Alves-Filho JC, Asquith DL,
Michels C, Millar NL, Reilly JH, Graham GJ, Liew FY, Miller AM and
McInnes IB: IL-33 induces skin inflammation with mast cell and
neutrophil activation. Eur J Immunol. 41:2229–2237. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Balato A, Di Caprio R, Canta L, Mattii M,
Lembo S, Raimondo A, Schiattarella M, Balato N and Ayala F: IL-33
is regulated by TNF-α in normal and psoriatic skin. Arch Dermatol
Res. 306:299–304. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Puzenat E, Bronsard V, Prey S, Gourraud
PA, Aractingi S, Bagot M, Cribier B, Joly P, Julien D, Le Maitre M,
et al: What are the best outcome measures for assessing plaque
psoriasis severity? A systematic review of the literature. J Eur
Acad Dermatol Venereol. 24:(Suppl 2). 10–16. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vageli D, Daniil Z, Dahabreh J, Karagianni
E, Vamvakopoulou DN, Ioannou MG, Scarpinato K, Vamvakopoulos NC,
Gourgoulianis KI and Koukoulis GK: Phenotypic mismatch repair hMSH2
and hMLH1b gene expression profiles in primary non-small cell lung
carcinomas. Lung Cancer. 64:282–288. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Saraceno R, Saggini A, Pietroleonardo L
and Chimenti S: Infliximab in the treatment of plaque type
psoriasis. Clin Cosmet Investig Dermatol. 2:27–37. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Panzer R, Blobel C, Fölster-Holst R and
Proksch E: TLR-2 and TLR4 expression in atopic dermatitis, contact
dermatitis and psoriasis. Exp Dermatol. 23:364–366. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hata TR, Afshar M, Miller J, Two AM, Kotol
P, Jackson M, Alexandrescu DT, Kabigting F, Gerber M, Lai Y and
Gallo RL: Etanercept decreases the innate immune wounding response
in psoriasis. Exp Dermatol. 22:599–601. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Garcia Rodriguez, Arias-Santiago S,
Perandrés-López R, Castellote L, Zumaquero E, Navarro P,
Buendía-Eisman A, Ruiz JC, Orgaz-Molina J and Sancho J: Increased
gene expression of Toll-like receptor 4 on peripheral blood
mononuclear cells in patients with psoriasis. J Eur Acad Dermatol
Venereol. 27:242–250. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Meephansan J, Komine M, Tsuda H, Karakawa
M, Tominaga S and Ohtsuki M: Expression of IL-33 in the epidermis:
The mechanism of induction by IL-17. J Dermatol Sci. 71:107–114.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Choi YS, Park JA, Kim J, Rho SS, Park H,
Kim YM and Kwon YG: Nuclear IL-33 is a transcriptional regulator of
NF-κB p65 and induces endothelial cell activation. Biochem Biophys
Res Commun. 421:305–311. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ali S, Mohs A, Thomas M, Klare J, Ross R,
Schmitz ML and Martin MU: The dual function cytokine IL-33
interacts with the transcription factor NF-κB to dampen
NF-κB-stimulated gene transcription. J Immunol. 187:1609–1616.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li C, Li H, Jiang Z, Zhang T, Wang Y, Li
Z, Wu Y, Ji S, Xiao S, Ryffel B, et al: Interleukin-33 increases
antibacterial defense by activation of inducible nitric oxide
synthase in skin. PLoS Pathog. 10:e10039182014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hägg D, Eriksson M, Sundström A and
Schmitt-Egenolf M: The higher proportion of men with psoriasis
treated with biologics may be explained by more severe disease in
men. PLoS One. 8:e636192013. View Article : Google Scholar : PubMed/NCBI
|
